Biomarin Pharmaceutical - Registered Shares Return on Equity

Biomarin Pharmaceutical - Registered Shares (BMRN) currently reports a ROE of 1.15%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Biomarin Pharmaceutical - Registered Shares's ROE history and peer comparisons.

Biomarin Pharmaceutical - Registered Shares's ROE of 1.15% is lower than the Healthcare sector average of 11.15%. That is roughly 89.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biomarin Pharmaceutical - Registered Shares's current 1.15% should be judged against Healthcare norms (sector average: 11.15%) and against BMRN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1.15%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Biomarin Pharmaceutical - Registered Shares, and consider following BMRN for alerts when major investors trade the stock.

Biomarin Pharmaceutical - Registered Shares is classified in the Healthcare sector. On ROE, it currently shows 1.15% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BMRN with unrelated industries.